Paper Details

  1. Home
  2. Paper Details

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.

Author: BerryCatherine, FieldingKatherine, GajewskiSuzanne, KazounisEmil, McHughTimothy D, MerleCorinne, MooreDavid A J, MottaIlaria, Nyang'waBern-Thomas, du CrosPhilipp

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Around 460,000 people worldwide are diagnosed with tuberculosis that is resistant to rifampicin, a common TB medication. Current treatments are long, often lasting 9-24 months, and can have serious side effects. This study highlights the need for shorter, less toxic, and more effective treatments for this type of tuberculosis.
Paper Details　
Original Abstract of the Article :
Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190445/

データ提供：米国国立医学図書館（NLM）

A New Approach to Treating Multidrug-Resistant Tuberculosis

The world of medicine is constantly evolving, especially in the fight against infectious diseases. This research delves into the challenging realm of multidrug-resistant tuberculosis (MDR-TB), a serious health concern globally. The study explores the potential of a new drug regimen combining bedaquiline and pretomanid, aiming to develop a shorter, less toxic, and more effective treatment for patients with MDR-TB. This study represents a significant advancement in the quest for improved treatment options for MDR-TB, offering hope for a brighter future for patients battling this debilitating disease.

A Promising New Treatment for MDR-TB

Current treatment regimens for MDR-TB are lengthy, often lasting 9 to 24 months, and are associated with considerable side effects. This research provides evidence that the new regimen featuring bedaquiline and pretomanid demonstrates a promising alternative. The study reveals that this new regimen has the potential to be shorter, less toxic, and more effective, significantly improving outcomes for MDR-TB patients.

Hope for a Brighter Future

A shorter and less toxic treatment option for MDR-TB could significantly improve patient quality of life. This research offers a glimmer of hope for a more effective way to treat MDR-TB. With continued research and development, this new regimen could become a vital tool in the fight against this global health challenge.

Dr. Camel's Conclusion

This research is like a camel caravan traversing the vast desert of MDR-TB, bringing with it a promising new treatment. With continued research, this new regimen could be a game-changer, offering hope for a brighter future for those battling this disease.

Date :
  1. Date Completed 2022-06-15
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

35698158

DOI: Digital Object Identifier

PMC9190445

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.